Novo Nordisk has received a "Sell" rating due to growing competition from Eli Lilly and internal challenges like expiring patents and manufacturing issues. An analyst set a cautious price target of $47, reflecting concerns over flat to negative growth in sales and profits for 2026. Despite its leadership in GLP-1 drugs for diabetes and obesity, Novo Nordisk's market advantage is eroding as rivals advance with new drug mechanisms. The company's future outlook remains uncertain amid these pressures.
Canada has enacted retaliatory tariffs on $20 billion worth of U.S. goods, including steel, aluminum, dairy, and electronics, escalating an 18-month trade dispute. These tariffs range from 15% to 50% and affect key sectors, putting pressure on North ...
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four key metrics. Since its inception, it has delivered an average return of 14.89%, marginally beating SCHD's 14....
